Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SEPN

Septerna Inc

Dec 26 • 02:23PM ET

25.85

Dollar change -0.05
Percentage change -0.19	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM IWO SCHA IWN VTI RSSL SCHB IWV VXF UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	30.04%	Shs Outstand	44.40M	Perf Week	15.40%
Market Cap	1.15B	Forward P/E	-	EPS next Y	-	Insider Trans	56.59%	Shs Float	31.06M	Perf Month	11.18%
Income	-	PEG	-	EPS next Q	-0.69	Inst Own	31.19%	Short Float	3.25%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	2.46	Perf Half Y	-
Book/sh	-1.97	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.01M	Perf Year	-
Cash/sh	2.94	P/C	8.79	EPS next 5Y	-	ROE	-	52W Range	18.62 - 28.99	Perf YTD	20.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-10.83%	Beta	-
Dividend TTM	-	Quick Ratio	10.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	38.83%	ATR (14)	2.34
Dividend Ex-Date	-	Current Ratio	10.08	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	58.13	Volatility	13.37% 9.74%
Employees	-	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	43.67
Option/Short	No / Yes	LT Debt/Eq	0.18	EPS Q/Q	-	Payout	-	Rel Volume	0.21	Prev Close	25.90
Sales Surprise	-100.00%	EPS Surprise	-42.94%	Sales Q/Q	-	Earnings	Nov 20 BMO	Avg Volume	410.60K	Price	25.85
SMA20	6.35%	SMA50	9.37%	SMA200	9.37%	Trades		Volume	65,710	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-24	Initiated	Wells Fargo	Overweight	$43
Nov-19-24	Initiated	TD Cowen	Buy
Nov-19-24	Initiated	JP Morgan	Overweight	$38
Nov-19-24	Initiated	Cantor Fitzgerald	Overweight	$50

Dec-18-24 08:00AM	Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 11:12PM	Septerna, Inc. Reports Q3 2024 Financials and Progress (TipRanks)
Nov-20-24 07:00AM	Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
05:10AM	Septerna initiated with an Overweight at JPMorgan (TipRanks)
Oct-30-24 04:41PM	Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering (GlobeNewswire) +12.32%
09:47PM	Loading…
Oct-24-24 09:47PM	Septerna Prices Upsized Initial Public Offering (GlobeNewswire)

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '24	Buy	18.00	4,170,000	75,060,000	5,523,915	Oct 30 06:12 PM
Third Rock Ventures V, L.P.	10% Owner	Oct 28 '24	Buy	18.00	370,500	6,669,000	6,215,591	Oct 28 04:53 PM
Third Rock Ventures V, L.P.	10% Owner	Oct 28 '24	Buy	18.00	279,500	5,031,000	3,152,456	Oct 28 04:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SEPN

Septerna Inc

Upgrade your FINVIZ experience